Perspective Therapeutics Total Cash From Financing Activities Over Time
| CATX Stock | 4.30 0.00 0.00% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Perspective Therapeutics Performance and Perspective Therapeutics Correlation. Perspective |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Perspective Therapeutics. If investors know Perspective will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Perspective Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.33) | Revenue Per Share 0.029 | Quarterly Revenue Growth 0.337 | Return On Assets (0.14) | Return On Equity (0.27) |
The market value of Perspective Therapeutics is measured differently than its book value, which is the value of Perspective that is recorded on the company's balance sheet. Investors also form their own opinion of Perspective Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Perspective Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Perspective Therapeutics' market value can be influenced by many factors that don't directly affect Perspective Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Perspective Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Perspective Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Perspective Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Cash From Financing Activities Analysis
Compare Perspective Therapeutics and related stocks such as Orthopediatrics Corp, Orthofix Medical, and Sight Sciences Total Cash From Financing Activities Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KIDS | 19.7 M | 19.7 M | 19.7 M | 19.7 M | 19.7 M | (98 K) | 3.6 M | 54.7 M | 39.7 M | 91 M | 46.7 M | 6 K | 136 M | 7.3 M | 6.9 M |
| OFIX | 14.3 M | (13.7 M) | (138.6 M) | (38.4 M) | (20 M) | 25.1 M | (46.1 M) | 3.5 M | 3 M | (10.7 M) | 3.2 M | (3.6 M) | (78 K) | 65.3 M | 68.6 M |
| SGHT | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 12.2 M | 42.7 M | 73.4 M | 252.5 M | 1.2 M | 1.1 M | 1 M |
| NPCE | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 21.4 M | 55 M | 102.5 M | 490 K | 8.1 M | 7.7 M |
| CVRX | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 29.5 M | 49.8 M | 111.9 M | 7.5 M | 24 M | 35.6 M |
| PAVM | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.2 M | 4.3 M | 7.6 M | 15.5 M | 11.4 M | 33 M | 104.3 M | 38.2 M | 31.2 M | 27.3 M |
| HYPR | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 4.7 M | 60.9 M | 176.8 M | 7 K | 174 K | 165.3 K |
| ELMD | 877.4 K | (368.8 K) | (2 M) | (127.7 K) | (61.2 K) | (62.3 K) | (53.6 K) | 11.7 K | (851.2 K) | (548 K) | (1.2 M) | (1.5 M) | (380 K) | 36 K | 49.6 K |
| SRDX | 15.6 M | (83.2 M) | (17.8 M) | (12.6 M) | (19.6 M) | (199 K) | (6.5 M) | (3.4 M) | (11 M) | (4.6 M) | 10.2 M | (375 K) | 18.4 M | (3 M) | (3.1 M) |
| FNA | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 6.5 M | 24 M | 131.1 M | 39.5 M | 128.7 M | 72.6 M |
| LIVN | 26.1 M | (46.7 M) | (18.8 M) | (37.3 M) | (48.3 M) | (18.1 M) | (124.3 M) | 11.3 M | (42.3 M) | 146.6 M | 310.8 M | (181.5 M) | 280.1 M | 21.5 M | 15.9 M |
| LUNG | 897 K | 897 K | 897 K | 897 K | 1.3 M | 3.2 M | 1.6 M | 5.3 M | 12.1 M | 45.6 M | 234.8 M | 4.5 M | 2.5 M | 21.4 M | 33.3 M |
| SIBN | 4 M | 4 M | 4 M | 8.1 M | 38.1 M | 31.4 M | 24.8 M | 12.9 M | 115.2 M | 3.5 M | 136.4 M | (1.7 M) | 2.2 M | 90.9 M | 95.5 M |
Perspective Therapeutics and related stocks such as Orthopediatrics Corp, Orthofix Medical, and Sight Sciences Total Cash From Financing Activities description
My Equities
My Current Equities and Potential Positions
| Perspective Therapeutics | CATX |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Washington; U.S.A |
| Exchange | NYSE MKT Exchange |
null 4.3
Additional Tools for Perspective Stock Analysis
When running Perspective Therapeutics' price analysis, check to measure Perspective Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Perspective Therapeutics is operating at the current time. Most of Perspective Therapeutics' value examination focuses on studying past and present price action to predict the probability of Perspective Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Perspective Therapeutics' price. Additionally, you may evaluate how the addition of Perspective Therapeutics to your portfolios can decrease your overall portfolio volatility.